253 related articles for article (PubMed ID: 34001056)
1. Treatment patterns and outcomes of older patients with mantle cell lymphoma in an Asian population.
Yang X; Khoo LP; Chang EWY; Yang VS; Poon E; Somasundaram N; Farid M; Tang TPL; Tao M; Lim ST; Chan JY
BMC Cancer; 2021 May; 21(1):566. PubMed ID: 34001056
[TBL] [Abstract][Full Text] [Related]
2. Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era.
Gerson JN; Handorf E; Villa D; Gerrie AS; Chapani P; Li S; Medeiros LJ; Wang MI; Cohen JB; Calzada O; Churnetski MC; Hill BT; Sawalha Y; Hernandez-Ilizaliturri FJ; Kothari S; Vose JM; Bast MA; Fenske TS; Narayana Rao Gari S; Maddocks KJ; Bond D; Bachanova V; Kolla B; Chavez J; Shah B; Lansigan F; Burns TF; Donovan AM; Wagner-Johnston N; Messmer M; Mehta A; Anderson JK; Reddy N; Kovach AE; Landsburg DJ; Glenn M; Inwards DJ; Karmali R; Kaplan JB; Caimi PF; Rajguru S; Evens A; Klein A; Umyarova E; Pulluri B; Amengual JE; Lue JK; Diefenbach C; Fisher RI; Barta SK
J Clin Oncol; 2019 Feb; 37(6):471-480. PubMed ID: 30615550
[TBL] [Abstract][Full Text] [Related]
3. [Cytarabine and hematopoietic cell transplantation for mantle cell lymphoma. Analysis of 20 patients].
Campbell J; Hurtado S; Kutz C; Soto K; Ernst D
Rev Med Chil; 2019; 147(1):9-17. PubMed ID: 30848759
[TBL] [Abstract][Full Text] [Related]
4. Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial.
Zoellner AK; Unterhalt M; Stilgenbauer S; Hübel K; Thieblemont C; Metzner B; Topp M; Truemper L; Schmidt C; Bouabdallah K; Krauter J; Lenz G; Dürig J; Vergote V; Schäfer-Eckart K; André M; Kluin-Nelemans HC; van Hoof A; Klapper W; Hiddemann W; Dreyling M; Hoster E;
Lancet Haematol; 2021 Sep; 8(9):e648-e657. PubMed ID: 34450102
[TBL] [Abstract][Full Text] [Related]
5. Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial.
Ladetto M; Cortelazzo S; Ferrero S; Evangelista A; Mian M; Tavarozzi R; Zanni M; Cavallo F; Di Rocco A; Stefoni V; Pagani C; Re A; Chiappella A; Balzarotti M; Zilioli VR; Gomes da Silva M; Arcaini L; Molinari AL; Ballerini F; Ferreri AJM; Puccini B; Benedetti F; Stefani PM; Narni F; Casaroli I; Stelitano C; Ciccone G; Vitolo U; Martelli M
Lancet Haematol; 2021 Jan; 8(1):e34-e44. PubMed ID: 33357480
[TBL] [Abstract][Full Text] [Related]
6. Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma.
Le Gouill S; Thieblemont C; Oberic L; Moreau A; Bouabdallah K; Dartigeas C; Damaj G; Gastinne T; Ribrag V; Feugier P; Casasnovas O; Zerazhi H; Haioun C; Maisonneuve H; Houot R; Jardin F; Van Den Neste E; Tournilhac O; Le Dû K; Morschhauser F; Cartron G; Fornecker LM; Canioni D; Callanan M; Béné MC; Salles G; Tilly H; Lamy T; Gressin R; Hermine O;
N Engl J Med; 2017 Sep; 377(13):1250-1260. PubMed ID: 28953447
[TBL] [Abstract][Full Text] [Related]
7. Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma.
Graf SA; Stevenson PA; Holmberg LA; Till BG; Press OW; Chauncey TR; Smith SD; Philip M; Orozco JJ; Shustov AR; Green DJ; Libby EN; Bensinger WI; Pagel JM; Maloney DG; Zhou Y; Cassaday RD; Gopal AK
Ann Oncol; 2015 Nov; 26(11):2323-8. PubMed ID: 26347113
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib maintenance after R-CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial.
Doorduijn JK; Zijlstra JM; Lugtenburg PJ; Kersten MJ; Böhmer LH; Minnema MC; MacKenzie MA; van Marwijk Kooij R; de Jongh E; Snijders TJF; de Weerdt O; van Gelder M; Hoogendoorn M; Leys RBL; Kibbelaar RE; de Jong D; Chitu DA; Van't Veer MB; Kluin-Nelemans HC
Br J Haematol; 2020 Aug; 190(3):385-393. PubMed ID: 32150297
[TBL] [Abstract][Full Text] [Related]
9. Autologous stem cell transplantation (ASCT) in patients with mantle cell lymphoma: a retrospective study of the Spanish lymphoma group (GELTAMO).
García-Noblejas A; Cannata-Ortiz J; Conde E; González Barca E; Gutiérrez N; Rojas R; Vidal MJ; Ramírez MJ; Jiménez-Ubieto A; García-Ruiz JC; Sancho JM; López A; Ríos Rull P; Novelli S; Albo C; Debén G; López-Guillermo A; Nicolás C; González de Villambrosia S; Mercadal S; Martín García-Sancho A; Arranz R
Ann Hematol; 2017 Aug; 96(8):1323-1330. PubMed ID: 28536895
[TBL] [Abstract][Full Text] [Related]
10. Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy.
Greenwell IB; Staton AD; Lee MJ; Switchenko JM; Saxe DF; Maly JJ; Blum KA; Grover NS; Mathews SP; Gordon MJ; Danilov AV; Epperla N; Fenske TS; Hamadani M; Park SI; Flowers CR; Cohen JB
Cancer; 2018 Jun; 124(11):2306-2315. PubMed ID: 29579328
[TBL] [Abstract][Full Text] [Related]
11. A multicenter retrospective comparison of induction chemoimmunotherapy regimens on outcomes in transplant-eligible patients with previously untreated mantle cell lymphoma.
Ng ZY; Bishton M; Ritchie D; Campbell R; Gilbertson M; Hill K; Ratnasingam S; Schwarer A; Manos K; Shorten S; Ng M; Nelson N; Xin L; De Mel Widanalage S; Sunny T; Purtill D; Poon M; Johnston A; Cochrane T; Lee HP; Hapgood G; Tam C; Opat S; Hawkes E; Seymour J; Cheah CY
Hematol Oncol; 2019 Aug; 37(3):253-260. PubMed ID: 30983008
[TBL] [Abstract][Full Text] [Related]
12. [Risk - adapted intensive induction therapy, autologous stem cell transplantation, and rituximab maintenance allow to reach a high 7-year survival rate in patients with mantle cell lymphoma].
Vorobyev VI; Gemdzhian EG; Dubrovin EI; Nesterova ES; Kaplanov KD; Volodicheva EM; Zherebtsova VA; Kravchenko SK
Ter Arkh; 2019 Jul; 91(7):41-51. PubMed ID: 32598735
[TBL] [Abstract][Full Text] [Related]
13. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network.
Hermine O; Hoster E; Walewski J; Bosly A; Stilgenbauer S; Thieblemont C; Szymczyk M; Bouabdallah R; Kneba M; Hallek M; Salles G; Feugier P; Ribrag V; Birkmann J; Forstpointner R; Haioun C; Hänel M; Casasnovas RO; Finke J; Peter N; Bouabdallah K; Sebban C; Fischer T; Dührsen U; Metzner B; Maschmeyer G; Kanz L; Schmidt C; Delarue R; Brousse N; Klapper W; Macintyre E; Delfau-Larue MH; Pott C; Hiddemann W; Unterhalt M; Dreyling M;
Lancet; 2016 Aug; 388(10044):565-75. PubMed ID: 27313086
[TBL] [Abstract][Full Text] [Related]
14. R-hyper-CVAD versus R-CHOP/cytarabine with high-dose therapy and autologous haematopoietic stem cell support in fit patients with mantle cell lymphoma: 20 years of single-center experience.
Widmer F; Balabanov S; Soldini D; Samaras P; Gerber B; Manz MG; Goede JS
Ann Hematol; 2018 Feb; 97(2):277-287. PubMed ID: 29147847
[TBL] [Abstract][Full Text] [Related]
15. Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial.
Kluin-Nelemans HC; Hoster E; Hermine O; Walewski J; Geisler CH; Trneny M; Stilgenbauer S; Kaiser F; Doorduijn JK; Salles G; Szymczyk M; Tilly H; Kanz L; Schmidt C; Feugier P; Thieblemont C; Zijlstra JM; Ribrag V; Klapper W; Pott C; Unterhalt M; Dreyling MH
J Clin Oncol; 2020 Jan; 38(3):248-256. PubMed ID: 31804876
[TBL] [Abstract][Full Text] [Related]
16. RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106.
Chen RW; Li H; Bernstein SH; Kahwash S; Rimsza LM; Forman SJ; Constine L; Shea TC; Cashen AF; Blum KA; Fenske TS; Barr PM; Phillips T; Leblanc M; Fisher RI; Cheson BD; Smith SM; Faham M; Wilkins J; Leonard JP; Kahl BS; Friedberg JW
Br J Haematol; 2017 Mar; 176(5):759-769. PubMed ID: 27992063
[TBL] [Abstract][Full Text] [Related]
17. Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation.
Budde LE; Guthrie KA; Till BG; Press OW; Chauncey TR; Pagel JM; Petersdorf SH; Bensinger WI; Holmberg LA; Shustov AR; Green DJ; Maloney DG; Gopal AK
J Clin Oncol; 2011 Aug; 29(22):3023-9. PubMed ID: 21730271
[TBL] [Abstract][Full Text] [Related]
18. Serum beta-2 microglobulin as a prognostic biomarker in patients with mantle cell lymphoma.
Yoo C; Yoon DH; Kim S; Huh J; Park CS; Park CJ; Lee SW; Suh C
Hematol Oncol; 2016 Mar; 34(1):22-7. PubMed ID: 25689467
[TBL] [Abstract][Full Text] [Related]
19. Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survival.
Shanmugasundaram K; Goyal S; Switchenko J; Calzada O; Churnetski MC; Kolla B; Bachanova V; Gerson JN; Barta SK; Gordon MJ; Danilov AV; Grover NS; Mathews S; Burkart M; Karmali R; Sawalha Y; Hill BT; Ghosh N; Park SI; Epperla N; Bond DA; Badar T; Blum KA; Hamadani M; Fenske TS; Malecek M; Kahl BS; Martin P; Guo J; Flowers CR; Cohen JB
Eur J Haematol; 2021 Sep; 107(3):301-310. PubMed ID: 33973276
[TBL] [Abstract][Full Text] [Related]
20. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
